Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma

Nat Med. 1998 Mar;4(3):321-7. doi: 10.1038/nm0398-321.


The cloning of the genes encoding cancer antigens has opened new possibilities for the treatment of patients with cancer. In this study, immunodominant peptides from the gp100 melanoma-associated antigen were identified, and a synthetic peptide, designed to increase binding to HLA-A2 molecules, was used as a cancer vaccine to treat patients with metastatic melanoma. On the basis of immunologic assays, 91% of patients could be successfully immunized with this synthetic peptide, and 13 of 31 patients (42%) receiving the peptide vaccine plus IL-2 had objective cancer responses, and four additional patients had mixed or minor responses. Synthetic peptide vaccines based on the genes encoding cancer antigens hold promise for the development of novel cancer immunotherapies.

Publication types

  • Clinical Trial

MeSH terms

  • Adult
  • Cancer Vaccines / therapeutic use*
  • Drug Therapy, Combination
  • Evaluation Studies as Topic
  • Female
  • HLA-A2 Antigen / immunology
  • Humans
  • Immunization
  • Interleukin-2 / therapeutic use*
  • Lung Neoplasms / secondary
  • Lung Neoplasms / therapy
  • Melanoma / therapy*
  • Membrane Glycoproteins / therapeutic use*
  • Middle Aged
  • Neoplasm Metastasis
  • Oligopeptides / therapeutic use*
  • Peptide Fragments / therapeutic use*
  • gp100 Melanoma Antigen


  • Cancer Vaccines
  • HLA-A2 Antigen
  • Interleukin-2
  • Membrane Glycoproteins
  • Oligopeptides
  • PMEL protein, human
  • Peptide Fragments
  • gp100 Melanoma Antigen